June 27, 2017 Licensing, IP, and Legal Product Launch

Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)

Basel, 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of Esbriet offers a reduced pill burden for patients with idiopathic pulmonary fibrosis (IPF) People with IPF now have the option of taking one Esbriet... Read more

June 27, 2017 Licensing, IP, and Legal Product Launch

Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)

Basel, 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of Esbriet offers a reduced pill burden for patients with idiopathic pulmonary fibrosis (IPF) People with IPF now have the option of taking one Esbriet... Read more

June 23, 2017 Licensing, IP, and Legal PR/Corporate Product Launch

New data at EAN show Roche’s OCREVUS™ (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis

Basel, 23 June 2017 New data at EAN show Roche’s OCREVUS™ (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis OCREVUS increased the number of patients with relapsing MS (RMS) and primary progressive MS (PPMS) who maintained No Evidence of Progression or Active Disease (NEPAD) versus Rebif (interferon beta-1a)... Read more

June 21, 2017 Licensing, IP, and Legal

Brooks Automation to Participate in the CEO Investor Summit 2017

CHELMSFORD, Mass., June 21, 2017 (GLOBE NEWSWIRE) — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that the Company’s management will participate in the Ninth Annual CEO Investor Summit 2017, on Wednesday, July 12, 2017 in San Francisco, California. About The CEO Investor SummitThe CEO Summit is an accredited investor and publishing research analyst event that is... Read more

June 14, 2017 Lab Top-10 Licensing, IP, and Legal Life Science Tools

MilliporeSigma Awarded its First CRISPR Patent by Australian Patent Office

News Release June 14, 2017 Your Contact: Karen Tiano +1 978-495-0093 MilliporeSigma Awarded its First CRISPR Patent by Australian Patent Office Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR Similar patents pending in other countries; anticipate favorable outcomes Billerica, Massachusetts, June 14, 2017 — MilliporeSigma today announced... Read more

June 13, 2017 Licensing, IP, and Legal Life Science Tools

European Patent Office Confirms Grant of New ICE COLD-PCR Patent Exclusively Licensed to Transgenomic

OMAHA, Neb. (June 13, 2017) — Transgenomic, Inc. (OTCQB: TBIO) today reported that the European Patent Office (EPO) has confirmed its intention to grant a patent covering multiplexed ICE COLD-PCR (MX-ICP) technology in the European Union (EU). This Dana-Farber Cancer Institute patent is exclusively licensed to Transgenomic. Paul Kinnon, President and CEO of Transgenomic, commented,... Read more